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which exclusion or inclusion of cost data beyond trial has
on estimates of incremental costs: £2,640 and 
 

 
£7,130
respectively. The impact on the CEAC is shown to be
profound e.g. for a critical ICER of £500, the probability
that the treatment is cost-effective is increased by 0.732 if
beyond-trial costs are included.
CONCLUSIONS: Producers and consumers of cost-effec-
tiveness evidence need to be aware of the potential prob-
lem of asymmetry observed in our study since these re-
sults may have significant consequences on decision-
making. Economic theory would suggest that the beyond-
trial components should be excluded from our base case
analysis since they will have had no bearing on the ob-
served number of STPs.
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OBJECTIVES: to develop a standard methodology which
describes, inventories and compares the activities associ-
ated with the management of neutropenia with G-CSF in
chemo-treated cancer patients in three different settings:
inpatient care, outpatient care and home care; to collect
cost information associated with these activities for cal-
culating a cost per administration of G-CSF from the hos-
pital and home-care perspectives.
METHODS: The case study was conducted in Belgium
where the three different settings are permanently active.
Structured interviews of key personnel working in each set-
ting were taken first to obtain a detailed overview of the ac-
tivities, the frequencies, the resources used and related links
to other departments involved when G-CSF is administered.
Activities that had a high frequency of performance (at least
weekly) were then selected. Time measurements of these fre-
quent tasks, each with a fixed start- and end-point, were
then determined. Unit costs for each resource used and la-
bor costs were obtained from the administrative units.
RESULTS: Detailed activities in G-CSF management
were identified and a “map” for the product use in each
setting was established. Time measurements provided the
basic information for labor costing. Belgian estimates for
the cost per G-CSF administration, excluding the drug
cost, was estimated at 7.4 Euro for inpatient care, 4.4
Euro for outpatient care and 4.2 Euro for the home-care
setting. The main cost driver was found to be the cost of
taking and analyzing blood samples in the inpatient set-
ting where the cost of monitoring neutropenia is high
compared to the other settings. Excluding these costs
may favor the cost of hospital administration of G-CSF.
CONCLUSION: The methodology developed using the
ABC-method of investigation helps to compare the same
activities performed in administering G-CSF in different
settings. It clearly identifies where potential improve-
ments are possible so as to ensure efficient management
of G-CSF administration.
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OBJECTIVES:
 
 To assess uncertainty in a cost-utility
analysis (CUA) of adjunct entacapone treatment with
levodopa among patients with Parkinson’s disease (PD).
The purpose of the study was to apply probabilistic sensi-
tivity analysis in the comparison of alternative treatment
strategies using second-order simulation methods.
METHODS: Two treatment alternatives of PD, i.e.
levodopa with or without entacapone, were compared in
a cost-utility analysis. A Markov model was constructed
based on data from phase III clinical trials of entacapone
and a naturalistic health economic study of PD. Second
order simulation and bootstrap methods were employed
to provide understanding of the uncertainty due to sam-
pling variation. Cost and utility parameters were drawn
from empirical distributions. Parametric distributions
were used in the generation of transition probabilities.
RESULTS: Using a bootstrap sample size of 200 and
1000 patients, joint distribution of the mean incremental
costs and mean incremental utilities were calculated and
displayed in the cost-utility plane. The results for a boot-
strap sample of 1000 patients were all clustered in the
quadrant IV that includes situations in which entacapone
treatment yields gain in QALYs and cost savings. How-
ever, there was more variation with the sample of 200
patients. 85.4% of the bootstrap replications were in
quadrant IV. 12.1% of the joint distribution fell into
quadrant III indicating cost savings at the expense of loss
in QALYs. Gain in QALYs at extra costs resulted in
2.1% of the observations. Only 0.4% of the simulated re-
sults indicated less QALYs and increased costs.
CONCLUSIONS: The simulation methods used provided
valuable information on the sensitivity of the results of the
CUA. The probabilistic sensitivity analysis used in this
study strengthened confidence in the conclusions that enta-
capone as an adjunctive treatment to levodopa is both cost
saving and increases the quality of life of PD patients.
 
PMI8
 
DO HEALTH CARE PURCHASERS PREFER 
PAYING FOR LIFE EXTENSION OR
QUALITY OF LIFE IMPROVEMENT?
 
Kerrigan J, Knight C
Heron Evidence Development Ltd, Stevenage, UK
